CN1263861C - 压缩的eb病毒复制子 - Google Patents

压缩的eb病毒复制子 Download PDF

Info

Publication number
CN1263861C
CN1263861C CNB98810816XA CN98810816A CN1263861C CN 1263861 C CN1263861 C CN 1263861C CN B98810816X A CNB98810816X A CN B98810816XA CN 98810816 A CN98810816 A CN 98810816A CN 1263861 C CN1263861 C CN 1263861C
Authority
CN
China
Prior art keywords
sequence
nucleotide sequence
orip
less
ebna1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB98810816XA
Other languages
English (en)
Other versions
CN1278185A (zh
Inventor
B·塞德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of CN1278185A publication Critical patent/CN1278185A/zh
Application granted granted Critical
Publication of CN1263861C publication Critical patent/CN1263861C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

本发明公开了支持在哺乳动物细胞中进行游离复制的核酸序列。该核酸序列长度小于3kb，包括(a)经缺失的OriP序列，和(b)经缺失的EBNA1序列，它们可操作地与启动子相连。

Description

压缩的EB病毒复制子
发明背景
EB病毒是一种人疱疹病毒，具有以环状病毒DNA的稳定的游离型增殖为特征的潜伏期。有两个不连续DNA元件为潜伏期复制所必需：复制的顺式作用起点OriP，以及复制所需的唯一由病毒编码的蛋白EB核抗原1(EBNA1)(Yates et al.，Proc.Natl.Acad.Sci.USA81：3806-10，1984；Yates et al.Nature 313：812-5，1985)。由于EBNA1及OriP链段的巨大的尺寸，多数EBV载体十分巨大，约为10KB或更大(不含插入片段)。多数现存的EBV EBNA1及OriP的尺寸妨碍了可以包含于其他基因递送载体，如反转录病毒和腺病毒的改良表达载体的建立，以及压缩的基因表达和持续盒的构建。
发明简述
大体上，本发明以支持在哺乳动物细胞中游离复制的核酸序列为特征。核酸序列包含(a)经缺失的OriP序列和(b)经缺失的EBNA1序列，它们可操作地连接到启动子上，核酸序列的长度小于3KB，优选小于2KB，最优选小于1.8KB。
优选实施方案中，OriP序列大约包含SEQ ID NO：1的1-495位残基；EBNA1大约包含SEQ ID NO：1的627-1718位残基；核酸序列还包含多腺苷化共有序列(如，接近SEQ ID NO：2序列)；且启动子为病毒启动子。
在相关方面，本发明还以包含这一核酸序列的载体和细胞(如哺乳动物细胞，优选人细胞)为特征。
详述
首先描述附图。
图1是截短的EBV OriP和EBNA-1盒的序列。
图2是可用于与压缩EBV复制子相连的压缩的合成双向多腺苷化序列。
大量缺失和突变后，发现可能将EBV病毒游离复制所必需的顺式和反式作用元件嵌入小于2KB的片断中。特别是，图1所示用作压缩EBV复制子的1748bp的例举性片段(SEQ ID NO：1)。除多腺苷化共有序列之外，该片段含有有效表达EBNA-1蛋白所必需的所有序列。该片段是一Bg12 BamH1链段，在残基1-495含有OriP元件，在残基496-616含有来自单纯疱疹病毒1胸苷激酶的修饰的启动子，在残基627-1718含有经缺失和修饰的EBNA-1编码序列。基于该序列的质粒载体以游离基因的形式在非啮齿来源的转染细胞的核中复制(Yates等，1985，见上文)。
为从整体上使序列长度最小化，上述片段被设计插入到合适载体的双向多腺苷化序列的上游。图2中提供了压缩的合成双向多腺苷化序列(SEQ ID NO：2)。发现压缩EBV复制子可用于基因治疗载体，如，基因递送载体如表达载体。
其他实施方案包含于权利要求中。

Claims (8)

1.一种核酸序列，它在哺乳动物细胞中支持游离基因复制，所述核酸序列包括(a)经缺失的OriP序列，所述OriP序列包含SEQ ID NO：1的1-495位残基和(b)经缺失的EBNA1序列，所述EBNA1序列包含SEQ ID NO：1的627-1718位残基，它们可操作地连接到启动子上，所述核酸序列长度小于3kb。
2.权利要求1的核酸序列，所述核酸长度小于2kb。
3.权利要求1的核酸序列，所述核酸长度小于1.8kb。
4.权利要求1的核酸序列，其中所述核酸序列还包含多腺苷化共有序列。
5.权利要求4的核酸序列，其中所述多腺苷化共有序列包含SEQID NO：2。
6.权利要求1的核酸序列，其中所述启动子是病毒启动子。
7.包含权利要求1的核酸序列的载体，所述载体能以游离基因形式在转染细胞的核中复制。
8.包含权利要求1的核酸序列的细胞。
CNB98810816XA 1997-06-19 1998-04-14 压缩的eb病毒复制子 Expired - Fee Related CN1263861C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5020697P 1997-06-19 1997-06-19
US60/050206 1997-06-19
US60/050,206 1997-06-19

Publications (2)

Publication Number Publication Date
CN1278185A CN1278185A (zh) 2000-12-27
CN1263861C true CN1263861C (zh) 2006-07-12

Family

ID=21963948

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB98810816XA Expired - Fee Related CN1263861C (zh) 1997-06-19 1998-04-14 压缩的eb病毒复制子

Country Status (20)

Country Link
US (1) US6133025A (zh)
EP (1) EP1032418B1 (zh)
JP (1) JP2002505586A (zh)
KR (1) KR100569826B1 (zh)
CN (1) CN1263861C (zh)
AR (1) AR054291A1 (zh)
AT (1) ATE270341T1 (zh)
AU (1) AU744680B2 (zh)
BR (1) BR9810055A (zh)
CA (1) CA2293299A1 (zh)
DE (1) DE69824881T2 (zh)
DK (1) DK1032418T3 (zh)
ES (1) ES2224382T3 (zh)
HU (1) HUP0003971A3 (zh)
ID (1) ID24649A (zh)
PL (1) PL337528A1 (zh)
PT (1) PT1032418E (zh)
RU (1) RU2240348C2 (zh)
TR (1) TR199903155T2 (zh)
WO (1) WO1998057658A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10421950B2 (en) * 2001-05-07 2019-09-24 National Research Council Of Canada Enhanced production of recombinant proteins by transient transfection of suspension-growing mammalian cells
WO2009137911A1 (en) 2008-05-15 2009-11-19 National Research Counsil Of Canada Process, vectors and engineered cell lines for enhanced large-scale transfection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939088A (en) * 1987-02-18 1990-07-03 Meloy Laboratories Inc. Sustained production of recombinant gamma interferon using an Epstein-Barr virus replicon

Also Published As

Publication number Publication date
EP1032418A4 (en) 2002-01-02
WO1998057658A1 (en) 1998-12-23
HUP0003971A2 (en) 2001-03-28
AU744680B2 (en) 2002-02-28
US6133025A (en) 2000-10-17
ATE270341T1 (de) 2004-07-15
EP1032418B1 (en) 2004-06-30
RU2240348C2 (ru) 2004-11-20
CN1278185A (zh) 2000-12-27
KR20010013901A (ko) 2001-02-26
JP2002505586A (ja) 2002-02-19
AR054291A1 (es) 2007-06-20
ID24649A (id) 2000-07-27
AU7123998A (en) 1999-01-04
EP1032418A1 (en) 2000-09-06
PT1032418E (pt) 2004-10-29
DK1032418T3 (da) 2004-11-01
PL337528A1 (en) 2000-08-28
HUP0003971A3 (en) 2003-03-28
BR9810055A (pt) 2000-09-12
CA2293299A1 (en) 1998-12-23
KR100569826B1 (ko) 2006-04-11
TR199903155T2 (en) 2000-09-21
ES2224382T3 (es) 2005-03-01
DE69824881T2 (de) 2004-11-18
DE69824881D1 (de) 2004-08-05

Similar Documents

Publication Publication Date Title
US5707618A (en) Adenovirus vectors for gene therapy
Dorsch-Häsler et al. A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus.
Rechavi et al. Activation of a cellular oncogene by DNA rearrangement: possible involvement of an IS-like element
US6153436A (en) Method of gene delivery using wildtype adeno associated viral (AAV) vectors with insertions
Rawlins et al. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region
JP3159446B2 (ja) 組換えアデノウイルス
Van Craenenbroeck et al. Episomal vectors for gene expression in mammalian cells
US5849522A (en) Enhancer for eukaryotic expression systems
EP0848063A3 (en) Nucleic acid constructs containing hybrid promotors for use in gene therapy
Rixon et al. A tandemly reiterated DNA sequence in the long repeat region of herpes simplex virus type 1 found in close proximity to immediate-early mRNA 1
AU718772B2 (en) Adenovirus vectors for gene therapy
CN1263861C (zh) 压缩的eb病毒复制子
Jenson et al. Sequences of the Epstein-Barr virus (EBV) large internal repeat form the center of a 16-kilobase-pair palindrome of EBV (P3HR-1) heterogeneous DNA
Wang et al. Fifty-one kilobase HSV-1 plasmid vector can be packaged using a helper virus-free system and supports expression in the rat brain
Hübscher et al. The genetics of adeno-associated virus
Karlin Significant potential secondary structures in the Epstein-Barr virus genome.
US6291246B1 (en) DNA virus vectors and methods for their preparation
JPH02500801A (ja) 誘発的に発現された活性化因子タンパク質からの刺激下での組換え遺伝子の発現のための方法
Weichselbraun et al. Optimal replication of plasmids carrying polyomavirus origin regions requires two high-affinity binding sites for large T antigen
US6436693B1 (en) Method for helper virus-free packaging of a gene vector DNA
MXPA99011726A (es) Replicones de virus de epstein-barr compactos
CN1146657C (zh) 一种重组单纯疱疹病毒的构建及用途
CZ456599A3 (cs) Kompaktní replikony viru Epstein-barr
KR19990045043A (ko) 헬퍼바이러스 없이 유전자벡터ｄｎａ를 패키징하는 방법
Kazuo et al. The replication origin of pSC101: the nucleotide sequence and replication functions of the ori region

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060712